3-nitro-2-phenylaminopyridine | 34949-41-2

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 英文名称: 3-nitro-2-phenylaminopyridine
• 英文别名: 3-nitro-N-phenylpyridin-2-amine；2-Anilino-3-nitro-pyridin；2-phenylamino-3-nitropyridine；3-Nitro-2-anilino-pyridin
• CAS: 34949-41-2
• 化学式: C₁₁H₉N₃O₂
• mdl: MFCD00499523
• 分子量: 215.211
• InChiKey: PCCSYAWZVABITQ-UHFFFAOYSA-N

物化性质

• 熔点：
  74-75 °C(Solv: isopropanol (67-63-0))
• 沸点：
  349.4±27.0 °C(Predicted)
• 密度：
  1.340±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  70.7
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933399090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Nitro-N-phenylpyridin-2-amine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Nitro-N-phenylpyridin-2-amine
CAS number: 34949-41-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H9N3O2
Molecular weight: 215.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-nitro-2-phenylaminopyridine 在 钯 盐酸 、 三乙酰氧基硼氢化钠 、 溶剂黄146 作用下， 以 乙醇 、 二氯甲烷 、 乙酸乙酯 、 丙酮 为溶剂， 生成 2-N-phenylamino-3-N-isopropylaminopyridine
  参考文献：
  名称：

  PYRIDYL CARBENE PHOSPHORESCENT EMITTERS

  摘要：

  提供了包含咪唑卡宾配体的有机金属化合物，其中该配体具有与咪唑环融合的含氮环。具体来说，与咪唑环融合的含氮环可能包含一个或多个氮原子。这些化合物可能表现出高光致发光（PL）效率、高斯发射光谱和/或短激发态寿命。这些材料可能特别适用作为蓝色磷光发射体。

  公开号：

  US20120228583A1
• 作为产物：
  描述：

  2-氯-3-硝基吡啶 在 三乙胺 、 苯胺 作用下， 以 乙酸乙酯 、 正丁醇 为溶剂， 以85%的产率得到3-nitro-2-phenylaminopyridine
  参考文献：
  名称：

  PYRIDYL CARBENE PHOSPHORESCENT EMITTERS

  摘要：

  提供了包含咪唑卡宾配体的有机金属化合物，其中该配体具有与咪唑环融合的含氮环。具体来说，与咪唑环融合的含氮环可能包含一个或多个氮原子。这些化合物可能表现出高光致发光（PL）效率、高斯发射光谱和/或短激发态寿命。这些材料可能特别适用作为蓝色磷光发射体。

  公开号：

  US20120228583A1

文献信息

• Synthesis and biological evaluation of 1-benzyl-N-(2-(phenylamino)pyridin-3-yl)-1H-1,2,3-triazole-4-carboxamides as antimitotic agents
  作者：Budaganaboyina Prasad、V. Lakshma Nayak、P.S. Srikanth、Mirza Feroz Baig、N.V. Subba Reddy、Korrapati Suresh Babu、Ahmed Kamal

  DOI：10.1016/j.bioorg.2018.11.002

  日期：2019.3

  A library of 1-benzyl-N-(2-(phenylamino)pyridin-3-yl)-1H-1,2,3-triazole-4-carboxamides (7a–al) have been designed, synthesized and screened for their anti-proliferative activity against some selected human cancer cell lines namely DU-145, A-549, MCF-7 and HeLa. Most of them have shown promising cytotoxicity against lung cancer cell line (A549), amongst them 7f was found to be the most potent anti-proliferative

  1-苄基-甲库ñ - （2-（苯基氨基）吡啶-3-基）-1- ħ 1,2,3-三唑-4-甲酰胺（图7a-人）已经被设计，合成和筛选其对某些选定的人类癌细胞系DU-145，A-549，MCF-7和HeLa具有抗增殖活性。它们中的大多数已显示出对肺癌细胞系（A549）的有希望的细胞毒性，其中7f被发现是最有效的抗增殖同源物。此外，7f表现出与 标准E7010（IC 50值为2.15）相当的微管蛋白聚合抑制作用（IC 50值为2.04 µM）。 µM）。此外，流式细胞仪分析表明该化合物通过在A549细胞中以G 2 / M期的细胞周期停滞来诱导凋亡。通过检查线粒体膜电位进一步观察到了细胞凋亡的诱导，并且通过Hoechst染色以及膜联蛋白V-FITC分析也证实了凋亡的诱导。此外，分子对接研究表明化合物7f与β-微管蛋白的秋水仙碱结合位点结合。因此，7f通过在秋水仙碱活性位点的结合抑制微管蛋白聚合并诱导细胞凋亡而表现出抗增殖特性。
• Sulfonamide derivatives
  申请人：Eisai Co., Ltd.

  公开号：US05250549A1

  公开（公告）日：1993-10-05

  Sulfonamide derivatives of the general formula (I): ##STR1## wherein preferably R.sup.1 represents a lower alkoxy group, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are as defined in the specification, A and B may be the same or different from each other and each represents .dbd.N-- or .dbd.CH--, E represents an aromatic 6-membered cyclic group, which may have 1 or 2 nitrogen atoms in the ring, and may be substituted with 1 to 3 substituents which may be the same or different from one another with the proviso that a combination of R.sup.1 which is a hydrogen atom, lower alkyl group, nitro group or amino group which may be protected, R.sup.2 and R.sup.3 which are each a hydrogen atom, A and B which are each .dbd.CH-- and E which is a phenyl group which may be substituted with 1 to 3 substituents G which may be the same or different from one another is excluded, or pharmacologically acceptance salts of them.

  磺酰胺衍生物的通用公式(I)：##STR1## 其中，优选地，R.sup.1代表一个低烷氧基团，R.sup.2、R.sup.3、R.sup.4、R.sup.5、R.sup.6和R.sup.7如说明书所述定义，A和B可以相同也可以不同，每个代表.dbd.N--或.dbd.CH--, E代表一个芳香族6元环组，其中环中可能含有1个或2个氮原子，并且可以用1到3个可以相同也可以不同的取代基进行取代，前提是R.sup.1为氢原子、低烷基、硝基或可能被保护的氨基，R.sup.2和R.sup.3各自为氢原子，A和B各自为.dbd.CH--，E为可以被1到3个相同或不同的取代基G取代的苯基组被排除在外，或者是它们的药理可接受盐。
• HETEROCYCLIC COMPOUNDS AND METHODS OF USE
  申请人：Heald Robert

  公开号：US20120202785A1

  公开（公告）日：2012-08-09

  Formula I compounds, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological disorders, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  化学式I类化合物，包括立体异构体、几何异构体、互变异构体、代谢物及其药学上可接受的盐，对抑制PI3K的δ异构体以及治疗由脂质激酶介导的疾病，如炎症、免疫性疾病和癌症，具有用途。公开了利用化合物I类进行体外、体内和体内诊断、预防或治疗哺乳动物细胞中的这类疾病，或相关的病理状况的方法。
• Compositions and Methods for Treating Proliferation Disorders
  申请人：Arqule, Inc.

  公开号：US20160067260A1

  公开（公告）日：2016-03-10

  The present invention relates to methods of treating cell proliferative disorders, such as cancer or Proteus syndrome, by utilizing 3-(3-(4-(1-aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine or 3-(3-(4-(1-aminocyclobutyl)phenyl)-5-(3-morpholinophenyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine or N-(1-(3-(3-(4-(1-aminocyclobutyl)phenyl)-2-(2-aminopyridin-3-yl)-3H-imidazo[4,5-b]pyridin-5-yl)phenyl)piperidin-4-yl)-N-methylacetamide. The methods of the present invention can also relate to methods of treating cell proliferative disorders, such as cancer or Proteus syndrome, by utilizing the above compounds in combination with ((R)-6-(2-fluorophenyl)-N-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine).

  本发明涉及利用3-(3-(4-(1-氨基环丁基)苯基)-5-苯基-3H-咪唑并[4,5-b]吡啶-2-基)吡啶-2-胺或3-(3-(4-(1-氨基环丁基)苯基)-5-(3-吗啉基苯基)-3H-咪唑并[4,5-b]吡啶-2-基)吡啶-2-胺或N-(1-(3-(3-(4-(1-氨基环丁基)苯基)-2-(2-氨基吡啶-3-基)-3H-咪唑并[4,5-b]吡啶-5-基)苯基)哌啶-4-基)-N-甲基乙酰胺等化合物治疗细胞增殖性疾病，如癌症或普罗特斯综合征的方法。本发明的方法还可以涉及利用上述化合物与((R)-6-(2-氟苯基)-N-(3-(2-((2-甲氧基乙基)氨基)乙基)苯基)-5,6-二氢苯并[h]喹唑啉-2-胺)结合治疗细胞增殖性疾病，如癌症或普罗特斯综合征的方法。
• Heterocyclic compounds having anti-diabetic activity and their use
  申请人：Sankyo Company, Limited

  公开号：US05624935A1

  公开（公告）日：1997-04-29

  Compounds of formula (I): ##STR1## [wherein: X represents an unsubstituted or substituted indolyl, indolinyl, azaindolyl, azaindolinyl, imidazopyridyl or imidazopyrimidinyl group; Y represents an oxygen or sulfur atom; Z represents a 2,4-dioxothiazolidin-5-ylidenylmethyl, 2,4-dioxothiazolidin-5-ylmethyl, 2,4-dioxooxazolidin-5-ylmethyl, 3,5-dioxooxadiazolidin-2-ylmethyl or N-hydroxyureidomethyl group; R represents a hydrogen atom, an alkyl group, an alkoxy group, a halogen atom, a hydroxy group, a nitro group, an aralkyl group or a unsubstituted or substituted amino group; and m is an integer of from 1 to 5] have hypoglycemic and anti-diabetic activities.

  式(I)的化合物：##STR1## [其中：X代表未取代或取代的吲哚基、吲哚啉基、氮杂吲哚基、氮杂吲哚啉基、咪唑吡啶基或咪唑吡嘧啶基；Y代表氧原子或硫原子；Z代表2,4-二氧代噻唑啉-5-基甲基、2,4-二氧代噻唑啉-5-基甲基、2,4-二氧代噁唑啉-5-基甲基、3,5-二氧代噁二唑啉-2-基甲基或N-羟基脲基甲基；R代表氢原子、烷基、烷氧基、卤原子、羟基、硝基、芳基烷基或未取代或取代的氨基；m为1至5的整数]具有降血糖和抗糖尿病活性。

表征谱图